기업조회

본문 바로가기 주메뉴 바로가기

논문 기본정보

Effect of Empirically Applying β-Lactam Antibiotics for Treatment of Hospital-acquired Pneumonia on Pathogenic Bacteria

논문 개요

기관명, 저널명, ISSN, ISBN 으로 구성된 논문 개요 표입니다.
기관명 NDSL
저널명 中華醫院感染學雜志 = Chinese journal of nosocomiology
ISSN 1005-4529,
ISBN

논문저자 및 소속기관 정보

저자, 소속기관, 출판인, 간행물 번호, 발행연도, 초록, 원문UR, 첨부파일 순으로 구성된 논문저자 및 소속기관 정보표입니다
저자(한글) HOU, Dapeng,YANG, Fengxia,HAN, Chenghe
저자(영문)
소속기관
소속기관(영문)
출판인
간행물 번호
발행연도 2008-01-01
초록 OBJECTIVE To approach the effect of empirically applying β-lactam antibiotics for treatment of hospital- acquired pneumonia on distribution and antibiotic-resistance of pathogenic bacteria. METHODS To investigate 141 patients with hospital-acqired pneumonia in intensive care unit during Jan 2001-Oct 2005, and divide into 3 groups; third generation cephalosporin group; lactamase inhibitor group; and other lactam antibiotics group according to different initial antibacterial strategy, then analyze difference in distribution and antibiotic-resistance of pathogens among each group. RESULTS We acquired 164 strains of pathogens. Comparing with other two groups, the proportion of Gram-positive cocci in lactamase inhibitor group was higher significantly(P〈0.05). Drug-sensibility to β-lactam antibiotics in third generation cephalosporin group was lower than in other lactam antibiotics group, but this difference was not significant. Comparing with third generation cephalosporin group, in lactamase inhibitor group drug-sensibility of Gram-negative bacilli to β-lactam antibiotics increased significantly. CONCLUSIONS Either the efficacy or the effects on distribution and antibiotic-resistance of pathogens must be considered during selecting empiric antibacterial therapy. Meanwhile bacterial culture and susceptibility test must be rechecked in time.
원문URL http://click.ndsl.kr/servlet/OpenAPIDetailView?keyValue=03553784&target=NART&cn=NART51530902
첨부파일

추가정보

과학기술표준분류, ICT 기술분류,DDC 분류,주제어 (키워드) 순으로 구성된 추가정보표입니다
과학기술표준분류
ICT 기술분류
DDC 분류
주제어 (키워드) Hospital-acquired pneumonia,Empiric antibacterial therapy,β-Lactamase inhibitor,Pathogenic bacteri,Antibiotic-resistance